International Liver Cancer Association (ILCA) 15th Annual Conference

CME

Advertisement

ILCA 2021 will be the premier virtual forum for clinical, translational and basic researchers, physicians, and allied professionals across liver cancer-related disciplines to share best practices and findings and advance research in the pathogenesis, prevention, and treatment of liver cancer.

Rare liver tumors pre-conference Workshop - September 2, 3.15 - 5.30 p.m.

Single Topic Workshop "Molecular Diversity in HCC, Systemic Therapy, Surgery in the management of HCC: role of surgeons and of the radiologists; Radiology" - September 2, 5.45 - 6.45 p.m.

ILCA /EASL Join Symposium - September 2, 6.45 - 7.30 p.m.

On the agenda:

  • Telomere-induced DNA damage as an anticancer strategy
  • Basic Science Symposium: What has single cell genomics contributed to our understanding of liver cancer?
  • General Session: Molecular Pathogenesis, Cell Biology and Translational Research: 4 oral presenters are allowed 10 minutes for each presentation, followed by 30 minutes Q&A for all presentations. Q&A will be moderated
  • Past, present, and future of transplant oncology
  • Best Clinical Poster Session
  • ILCA Tumor Board
  • General Session: Epidemiology, Staging and Prognosis: 6 oral presenters are allowed 10 minutes for each presentation, followed by 30 minutes Q&A for all presentations. Q&A will be moderated
  • Industry Symposium
  • General Session 3: Diagnosis, Imaging and Biomarkers: 6 oral presenters are allowed 10 minutes for each presentation, followed by 30 minutes Q&A for all presentations. Q&A will be moderated
  • ILCA Debates: HCC down-staging to surgical therapies - Plenty of room & Still too many questions; Early transition to systemic therapies in patients at stage BCLC-B - Too early to recommend
~ 700 participants

Date

September 2-5, 2021

Location

Virtual Conference

Email

events@ilca-online.org

Website

ilca2021.org/


ILCA /EASL Join Symposium - September 2, 6.45 - 7.30 p.m.

On the agenda:
  • Telomere-induced DNA damage as an anticancer strategy
  • Basic Science Symposium: What has single cell genomics contributed to our understanding of liver cancer?
  • General Session: Molecular Pathogenesis, Cell Biology and Translational Research: 4 oral presenters are allowed 10 minutes for each presentation, followed by 30 minutes Q&A for all presentations. Q&A will be moderated
  • Past, present, and future of transplant oncology
  • Best Clinical Poster Session
  • ILCA Tumor Board
  • General Session: Epidemiology, Staging and Prognosis: 6 oral presenters are allowed 10 minutes for each presentation, followed by 30 minutes Q&A for all presentations. Q&A will be moderated
  • Industry Symposium
  • General Session 3: Diagnosis, Imaging and Biomarkers: 6 oral presenters are allowed 10 minutes for each presentation, followed by 30 minutes Q&A for all presentations. Q&A will be moderated
  • ILCA Debates: HCC down-staging to surgical therapies - Plenty of room & Still too many questions; Early transition to systemic therapies in patients at stage BCLC-B - Too early to recommend
~ 700 participants" />

Advertisement